Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AUP-16
Therapeutic Area : Podiatry
Study Phase : Phase I/ Phase II
Sponsor : Xbiome
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the license and collaboration agreement, Xbiome acquires exclusive development and commercial rights for all human use to Aurealis clinical stage DFU drug candidate AUP-16 in Mainland China, Hong Kong, Macao, and Taiwan.
Brand Name : AUP-16
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 28, 2022
Lead Product(s) : AUP-16
Therapeutic Area : Podiatry
Highest Development Status : Phase I/ Phase II
Sponsor : Xbiome
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?